Role of interlekin-35 as a biomarker in patients with newly diagnosed hashimoto’s thyroiditis

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Hakki
dc.contributor.authorÇakmak, Muzaffer
dc.contributor.authorCeydilek, Bilge
dc.contributor.authorDemir, Canan
dc.contributor.authorAktas, Aynur
dc.date.accessioned2025-10-24T18:06:42Z
dc.date.available2025-10-24T18:06:42Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjective. Interleukin-35 (IL-35), an interleukin-12 (IL-12) cytokine family member, is shown to be a potent immunosuppressive and anti-inflammatory cytokine. Inducible regulatory T cells (Tregs) produce IL-35 that mediates the immune inhibitory function of Tregs. Growing evidence revealed that upregulation of IL-35 expression may play a critical role in the prevention of autoimmune diseases in various experimental autoimmunity models and vice versa. Hashimoto’s thyroiditis (HT) is considered to be a Treg cell-related autoimmune disease with loss of self-tolerance. Methods. One hundred-twenty eight subjects, newly diagnosed hypothyroid HT patients [56 overt (Group 1), 72 subclinical hypothyroid (Group 2)] and 38 healthy controls (Group 3) were enrolled in the study. The levels of serum IL-35 were determined by enzyme-linked immunosor-bent assay (ELISA). Results. Serum IL-35 levels were lower in the HT group when compared with subclinical HT group [304.5 (834.6) pg/ml vs. 636.1 (1542.0) pg/ml, p=0.004] and control cases [304.5 (834.6) pg/ml vs. 1064.7 (2526.8) pg/ml, p<0.001]. Serum IL-35 levels were inversely associated with thyroid stimulating hormone (TSH; rs=–0.396, p<0.001) and anti-thyroid peroxidase antibodies (TPOAb; rs=–0.571, p<0.001) in whole group. Serum IL-35 were negatively associated with TSH (rs=–0.264, p=0.003) and TPOAb (rs=–0.735, p<0.001) in patients with Hashimoto’s thyroiditis (Group 1 + Group 2). Conclusion. The results suggest that IL-35 may play a role in the pathogenesis of HT. © 2020 Elsevier B.V., All rights reserved.
dc.identifier.doi10.1515/enr-2016-0009
dc.identifier.endpage61
dc.identifier.issn1336-0329
dc.identifier.issn1210-0668
dc.identifier.issue2
dc.identifier.pmid27560637
dc.identifier.scopus2-s2.0-84981287970
dc.identifier.scopusqualityQ3
dc.identifier.startpage55
dc.identifier.urihttps://doi.rog/10.1515/enr-2016-0009
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3160
dc.identifier.volume50
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherInstitute of Experimental Endocrinology macvetrev@fvm.ukim.edu.mk
dc.relation.ispartofEndocrine Regulations
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzScopus_20251023
dc.subjectAutoimmunity
dc.subjectHashimoto’s thyroiditis
dc.subjectHypothyroidism
dc.subjectIL-35
dc.subjectInflammation
dc.titleRole of interlekin-35 as a biomarker in patients with newly diagnosed hashimoto’s thyroiditis
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu